Open AccessSoluble IL‐2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy
Author(s) -
DUNCAN J. I.,
HORROCKS C.,
ORMEROD A. D.,
POWLES A. V.,
WHITING P. H.,
FRY L.,
THOMSON A. W
Publication year - 1991
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1991.tb05721.x
Subject(s) - psoriasis , il 2 receptor , puva therapy , psoriasis area and severity index , medicine , immunology , psoralen , dermatology , gastroenterology , pathology , t cell , biology , immune system , dna , genetics
SUMMARY A study was conducted to quantify soluble IL‐2 receptor (sIL‐2R) levels in sera of 57 chronic plaque psoriasis patients and correlate these measurements with disease activity and the numbers of IL‐2R‐positive (CD25 + ) lymphocytes in lesional biopsies of 11 cyclosporin A (CsA) and 13 psoralen plus ultraviolet radiation (PUVA) treated patients. Levels of sIL‐2R showed a strong correlation with the psoriasis area and severity index (PASI). CsA and PUVA significantly reduced the PASI and sIL‐2R levels to a similar degree after 4 weeks of treatment. Although the majority of CsA‐treated patients who were biopsied showed reductions in lesional CD25 + cells, these did not reach statistical significance; in five patients biopsied who had PUVA treatment, no consistent effect on the numbers of CD25 + cells was observed. A significant correlation was found between CD25 + cells in lesional biopsies and the PASI score.